Evidence-based·Last reviewed May 31, 2026·How we grade evidence

D-phenylalanine

Amino-acidBest taken away from food

D-phenylalanine (DPA) is the D-isomer of the essential amino acid phenylalanine. UNLIKE L-phenylalanine, the D-form is not used for protein synthesis and is not efficiently converted to tyrosine, dopamine, or norepinephrine in adults — so it isn't a 'mood precursor' on the L-phenylalanine pathway. Its proposed mechanism is enkephalinase inhibition (extending endogenous opioid signaling). Almost always sold as DL-phenylalanine (DLPA), a 50:50 mix. Old, small trials for chronic pain and depression; modern rigorous data is absent.

Quick decision guide

May help most

Adults exploring an adjunct for chronic pain who accept that the evidence is old, small, and mixed — and who aren't on MAOIs or other contraindicating medications.

Common dosing range

DLPA: 375–2,250 mg/day in divided doses. Pure DPA: 250–500 mg twice daily; rarely sold alone.

When to expect effects

If any benefit emerges, typically within 2–4 weeks at full dose.

Watch out for

Contraindicated in phenylketonuria. Don't combine with MAOIs (hypertensive crisis risk).

Evidence snapshot

Chronic pain (adjunct)Low (mixed)

Depression (adjunct)Low (very old trials)

Vitiligo (with UVA, L-phe more studied)Emerging (L-form)

Conversion to tyrosine / mood precursorDoesn't apply (D form)

What is it

D-phenylalanine (DPA) is the non-protein D-isomer of the essential amino acid phenylalanine. Unlike L-phenylalanine, the D form is not incorporated into proteins but has been studied for analgesic and mood effects via inhibition of enkephalin-degrading enzymes.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have chronic pain and want a low-risk 4–6 week adjunct trial alongside (not replacing) standard treatment

Your clinician suggests it as part of an integrative pain plan

You can buy a DLPA product with verified amino acid content

You accept the evidence is old, small, and mixed — and you'll stop if there's no clear benefit

Probably skip if…

You have phenylketonuria (PKU) or are pregnant with elevated phenylalanine risk — contraindicated

You're on an MAOI antidepressant — risk of hypertensive crisis

You're hoping DPA will boost mood by raising dopamine — the D-form doesn't convert to L-phenylalanine in adults; that's an L-form claim

You expect opioid-grade analgesia — DPA's enkephalinase mechanism produces only mild, inconsistent effects in trials

You're using it during pregnancy or breastfeeding — no human safety data

You're managing schizophrenia, bipolar disorder, or severe anxiety — phenylalanine compounds can worsen psychotic symptoms in susceptible individuals

Evidence at a glance

Goal	Effect	Best fit	Time
Chronic pain (adjunct) Limited Evidence	Open trials suggest ~60% subjective improvement; controlled trial showed no effect over placebo	Chronic pain patients exploring low-risk adjuncts alongside conventional management	2–4 weeks at full dose
Depression (adjunct) Limited Evidence	Comparable to imipramine in a 1979 open comparison (n=27); no modern replication	Adults exploring adjuncts under psychiatric supervision	30 days in the Beckmann trial
Vitiligo (with UVA — L-phenylalanine, not D) Limited Evidence	Modest repigmentation in L-phe + UVA trials; D-form doesn't apply	Not applicable to D-phenylalanine — see L-phenylalanine if exploring this indication	Months (in L-phe + UVA trials)
Tyrosine / dopamine precursor (does NOT apply to D-form) Mixed Evidence	Does not significantly raise tyrosine, dopamine, or norepinephrine in adult humans	Not applicable — DPA is the wrong isomer for the precursor pathway	N/A

Chronic pain (adjunct)

Limited Evidence

Effect: Open trials suggest ~60% subjective improvement; controlled trial showed no effect over placebo
Best fit: Chronic pain patients exploring low-risk adjuncts alongside conventional management
Time: 2–4 weeks at full dose

Depression (adjunct)

Limited Evidence

Effect: Comparable to imipramine in a 1979 open comparison (n=27); no modern replication
Best fit: Adults exploring adjuncts under psychiatric supervision
Time: 30 days in the Beckmann trial

Vitiligo (with UVA — L-phenylalanine, not D)

Limited Evidence

Effect: Modest repigmentation in L-phe + UVA trials; D-form doesn't apply
Best fit: Not applicable to D-phenylalanine — see L-phenylalanine if exploring this indication
Time: Months (in L-phe + UVA trials)

Tyrosine / dopamine precursor (does NOT apply to D-form)

Mixed Evidence

Effect: Does not significantly raise tyrosine, dopamine, or norepinephrine in adult humans
Best fit: Not applicable — DPA is the wrong isomer for the precursor pathway
Time: N/A

Evidence for 4 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Chronic pain (adjunct)

Supplement benefit

Limited Evidence

The proposed mechanism is enkephalinase inhibition — slowing the breakdown of endogenous enkephalins to extend the body's own opioid signaling. Open-label trials (Donzelle 1981) in chronic pain reported subjective improvement in around 60% of patients. The most rigorous double-blind placebo-controlled trial (Walsh 1986, n=20, crossover) found NO significant analgesic effect over placebo. Evidence is split between optimistic open-label data and disappointing controlled data. Effect, if present, is mild.

Effect size

Open trials suggest ~60% subjective improvement; controlled trial showed no effect over placebo

Time to effect

2–4 weeks at full dose

Best fit

Chronic pain patients exploring low-risk adjuncts alongside conventional management

Less likely

Acute or severe pain; anyone needing reliable analgesia

Bottom line: Low-risk to try for 4 weeks; don't expect more than mild, inconsistent relief.

Evidence is mixed

The most rigorous DLPA pain RCT (Walsh 1986) was negative; positive trials are open-label without placebo controls. The signal is mixed at best.

SourceWalsh et al., 1986 — PubMed — Pain· conflicting Donzelle et al., 1981 — PubMed — Anesthésie, Analgésie, Réanimation· conflicting

SourceDonzelle et al., 1981 — PubMed — Anesthésie, Analgésie, Réanimation Walsh et al., 1986 — PubMed — Pain Russell & McCarty, 2000 — PubMed — Medical Hypotheses

Depression (adjunct)

Supplement benefit

Limited Evidence

Beckmann 1979 compared DLPA vs imipramine in 27 endogenous-depression inpatients over 30 days — both groups improved by similar amounts on the Hamilton scale. The trial had no placebo arm, the sample was small, and the design wouldn't pass modern rigor. No subsequent large RCT has confirmed DLPA as an antidepressant. The L-form (NOT D) is the one with a plausible pathway to mood neurotransmitters; using DLPA mixes L and D and confounds attribution.

Effect size

Comparable to imipramine in a 1979 open comparison (n=27); no modern replication

Time to effect

30 days in the Beckmann trial

Best fit

Adults exploring adjuncts under psychiatric supervision

Less likely

Anyone needing first-line depression treatment; severe or treatment-resistant depression

Bottom line: Old, unreplicated evidence. Not a first-line antidepressant; talk to your prescriber before substituting.

SourceBeckmann et al., 1979 — PubMed — Arzneimittelforschung

Vitiligo (with UVA — L-phenylalanine, not D)

Limited Evidence

Oral L-phenylalanine combined with UVA phototherapy has been studied for vitiligo with modest repigmentation effects. This evidence is for the L-form, NOT the D-form. DLPA contains 50% L-phenylalanine, which is the relevant component. Pure D-phenylalanine wouldn't be appropriate for this indication.

Effect size

Modest repigmentation in L-phe + UVA trials; D-form doesn't apply

Time to effect

Months (in L-phe + UVA trials)

Best fit

Not applicable to D-phenylalanine — see L-phenylalanine if exploring this indication

Less likely

Anyone trying DPA specifically for vitiligo — wrong isomer

Bottom line: Wrong isomer for vitiligo. The L-form (with UVA) is the version studied.

SourceFriedman, 1999 — PubMed — Journal of Agricultural and Food Chemistry

Tyrosine / dopamine precursor (does NOT apply to D-form)

Mixed Evidence

L-phenylalanine is converted to tyrosine by phenylalanine hydroxylase, and tyrosine becomes dopamine and norepinephrine. The D-form is NOT efficiently converted to L-phenylalanine in adult humans (human D-amino-acid oxidase activity is low). DPA therefore does not function as a precursor to mood/focus neurotransmitters. Marketing of DPA as a 'dopamine booster' or 'mood enhancer' on the precursor pathway is misleading — that's an L-phenylalanine or L-tyrosine claim, not a DPA claim.

Effect size

Does not significantly raise tyrosine, dopamine, or norepinephrine in adult humans

Time to effect

N/A

Best fit

Not applicable — DPA is the wrong isomer for the precursor pathway

Less likely

Anyone hoping DPA will function as L-tyrosine or L-phenylalanine for focus/mood

Bottom line: Wrong isomer. Use L-phenylalanine or L-tyrosine if that's your target.

SourceFriedman, 1999 — PubMed — Journal of Agricultural and Food Chemistry

How it works

D-phenylalanine inhibits enkephalinase and carboxypeptidase A, enzymes that degrade endogenous opioid peptides (enkephalins). The proposed result is enhanced endogenous opioid signaling, potentially reducing pain perception and improving mood. Clinical evidence is weak and mixed. The DL-mix (DLPA) is more commonly sold and combines D-PA's putative analgesic effect with L-PA's role as a tyrosine and dopamine precursor.

How to take it

1. Typical dose

• DLPA (the common form): 375–2,250 mg/day total, in divided doses • Pure D-phenylalanine: 250–500 mg twice daily; rarely sold as a standalone • Start at the lower end (e.g. 500 mg DLPA twice daily) for the first week • Trial doses for pain trials ranged from 1,000 mg to 4,500 mg/day total DLPA

2. Higher studied dose

Up to ~4,500 mg/day DLPA has been used in older pain trials. Doses above this don't have evidence support and side effects (headache, GI upset, BP rise) become more likely.

3. Timing

Take 30–60 minutes before meals on an empty stomach if possible — large neutral amino acids in food compete for blood-brain barrier transport. Avoid evening doses (mild stimulant-like effect can disrupt sleep). Don't take in late afternoon if you're prone to insomnia.

4. With food

On empty stomach (30–60 min before meals).

5. Split dosing

Split into 2–3 daily doses (e.g. morning, midday, early afternoon). Avoid the last dose after early afternoon to protect sleep.

6. How long to try

Trial duration was typically 30 days for depression studies and weeks-to-months for pain trials. Re-evaluate after 4–6 weeks. If no clear benefit, stop — there's no rationale for continuing indefinitely without effect.

What to track

Pain severity (0–10 scale) for chronic pain use

Mood / depression rating for mood use

Sleep quality (DPA can cause insomnia if dosed late)

Blood pressure (especially if on antihypertensives or MAOIs)

Headache, jitteriness, GI upset

Bottom line: Start at 500 mg DLPA twice daily, before meals, no later than early afternoon. Try for 4–6 weeks. Stop if no clear benefit or if side effects bother you.

4 commercial forms

Compare the main delivery options and what they’re best suited for.

DL-phenylalanine (DLPA, 50:50 mix)

Standard supplement form

By far the most common form sold. Mixes the L-isomer (mood/protein precursor) and the D-isomer (proposed enkephalinase inhibitor). Almost all clinical-trial evidence is for DLPA, not pure D-phenylalanine.

Both isomers absorbed; the D-form is not efficiently converted to L in humans.

Pure D-phenylalanine (DPA)

Rare; limited evidence

Standalone D-isomer. Rarely sold. The mechanism-of-interest (enkephalinase inhibition) is attributed to this form, but most pain-trial evidence is on DLPA mixtures.

Same absorption as L-form; minimal conversion to L in adults.

L-phenylalanine (the other isomer)

Different molecule, different use

The biologically used isomer — incorporated into proteins, converted to tyrosine/dopamine/norepinephrine. Used for vitiligo (with UVA) and as a mood/focus support. Different evidence base and contraindication profile.

Efficient conversion to tyrosine and downstream neurotransmitters.

Combination DLPA + 5-HTP / SAMe products

Higher interaction risk

Marketed for 'mood support.' The DLPA contributes L-phenylalanine to the catecholamine pathway, 5-HTP feeds the serotonin pathway. Stacking raises serotonin-syndrome and MAOI-interaction concerns; avoid without clinical oversight.

Multiple active components; effects and risks are harder to attribute.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

headachemild nausea / heartburnjitterinessinsomnia (if dosed late)transient blood pressure elevation

Serious risks

Phenylketonuria (PKU): contraindicated. People with PKU cannot metabolize phenylalanine; any phenylalanine source (L, D, or DL) can cause neurological harm and is strictly avoided.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
MAOI antidepressants (selegiline, phenelzine, tranylcypromine, isocarboxazid): risk of hypertensive crisis. Phenylalanine is a tyrosine precursor and tyrosine becomes norepinephrine — MAOIs prevent norepinephrine breakdown, leading to dangerous BP spikes. Avoid combination.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
Tardive dyskinesia patients on antipsychotics: phenylalanine may worsen abnormal movements in some case reports. Avoid.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
Schizophrenia or psychotic-spectrum disorders: phenylalanine can theoretically worsen psychotic symptoms through dopamine pathway loading. Use only under psychiatric supervision.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

Who should avoid it

Anyone with phenylketonuria (PKU) or variants of phenylalanine metabolism disorders.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
Anyone taking an MAOI antidepressant (selegiline, phenelzine, tranylcypromine, isocarboxazid).
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
Pregnant or breastfeeding women — no human safety data; standard prenatal protein intake is sufficient.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
People with schizophrenia, bipolar disorder, or tardive dyskinesia — without psychiatric oversight.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
People with significant hypertension or on multiple BP medications — DPA can transiently raise BP.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox
People with melanoma or risk factors for melanoma — phenylalanine is a tyrosine precursor and tyrosine is a precursor to melanin; theoretical caution.
SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

Pregnancy & breastfeeding

Avoid in pregnancy and breastfeeding. There's no human safety data for supplemental DPA or DLPA during pregnancy. Dietary L-phenylalanine from protein-rich foods is essential and safe at normal intakes; isolated supplementation has no demonstrated benefit to offset unknown risks. Phenylalanine restriction is medically required in maternal PKU.

SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

Bottom line: Generally safe at typical doses for non-PKU adults not on MAOIs. The contraindication list is the part to memorize.

Interactions

MAOI antidepressants (selegiline, phenelzine, tranylcypromine, isocarboxazid, rasagiline)Major

Phenylalanine → tyrosine → norepinephrine pathway. MAOIs block norepinephrine breakdown, so high phenylalanine intake can cause hypertensive crisis. Avoid combination strictly.

SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

antipsychotics (haloperidol, risperidone, olanzapine, etc.)Moderate

Phenylalanine loading may worsen tardive dyskinesia in susceptible patients on antipsychotics. Use only under psychiatric supervision.

SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

Levodopa (for Parkinson's)Moderate

Phenylalanine and levodopa compete for the same intestinal and blood-brain barrier transporter (LAT1). Taking phenylalanine close to levodopa doses can reduce levodopa absorption and clinical effect. Separate by 1–2 hours.

SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

antihypertensive medicationsMinor

DPA can transiently raise blood pressure in some users. May reduce antihypertensive effect; monitor BP after starting.

SourceLiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox

stimulants (caffeine, ADHD medications)Minor

Additive stimulant-like effects (jitteriness, anxiety, insomnia). Avoid evening combinations.

Food sources

Food	Amount	%DV
Beef, lean	3 oz (~1.4 g L-phenylalanine, no DPA)	—
Chicken breast, cooked	3 oz (~1.2 g L-phenylalanine, no DPA)	—
Salmon, cooked	3 oz (~1.1 g L-phenylalanine, no DPA)	—
Soybeans, cooked	½ cup (~0.8 g L-phenylalanine, no DPA)	—
Eggs, large	1 egg (~0.4 g L-phenylalanine, no DPA)	—
Cottage cheese, low-fat	½ cup (~0.7 g L-phenylalanine, no DPA)	—
Pumpkin seeds, roasted	1 oz (~0.4 g L-phenylalanine, no DPA)	—

Beef, lean

Amount: 3 oz (~1.4 g L-phenylalanine, no DPA)
%DV: —

Chicken breast, cooked

Amount: 3 oz (~1.2 g L-phenylalanine, no DPA)
%DV: —

Salmon, cooked

Amount: 3 oz (~1.1 g L-phenylalanine, no DPA)
%DV: —

Soybeans, cooked

Amount: ½ cup (~0.8 g L-phenylalanine, no DPA)
%DV: —

Eggs, large

Amount: 1 egg (~0.4 g L-phenylalanine, no DPA)
%DV: —

Cottage cheese, low-fat

Amount: ½ cup (~0.7 g L-phenylalanine, no DPA)
%DV: —

Pumpkin seeds, roasted

Amount: 1 oz (~0.4 g L-phenylalanine, no DPA)
%DV: —

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

DLPA (50:50 DL-phenylalanine) is the standard form — most clinical evidence is on DLPA, not isolated DPA

Mg of DLPA or DPA disclosed per serving (clearly listed, not buried in a 'pain blend')

Single-ingredient capsule if possible — combination products with St John's Wort or 5-HTP add interaction risks

Third-party tested (USP, NSF, ConsumerLab) for amino acid content and purity

Pharmaceutical-grade amino acid source

Vegetarian/vegan capsule shell if relevant

Be skeptical of…

'Dopamine booster' or 'natural antidepressant' — these are L-phenylalanine claims, not DPA claims; the D-form doesn't convert to L in adults

'Replaces opioid painkillers' — DPA's enkephalinase mechanism is mild and inconsistent; not a substitute for prescribed analgesia

'PEA precursor' for mood — phenethylamine claims are L-phenylalanine, not D

Mega-dose 'pain blends' with multiple actives — masks side effects and interactions

Combination products with 5-HTP, SAMe, or St John's Wort — increases serotonin syndrome and MAOI-like interaction risk

'Endorphin booster' as a workout / mood claim — speculative and not supported by trials

Frequently asked questions

Is D-phenylalanine a painkiller?⌄

Proposed mechanism is enhancing endogenous opioids. Clinical evidence is weak. Not a substitute for proper pain management.

Is DLPA the same as DPA?⌄

DLPA is a 50/50 mix of D and L isomers. Pure DPA is less common.

References by claim

Chronic pain (adjunct)

Walsh et al., 1986 — PubMed — Pain (1986) link

Donzelle et al., 1981 — PubMed — Anesthésie, Analgésie, Réanimation (1981) link

Russell & McCarty, 2000 — PubMed — Medical Hypotheses (2000) link

Depression (adjunct)

Beckmann et al., 1979 — PubMed — Arzneimittelforschung (1979) link

Vitiligo (with UVA — L-phenylalanine, not D)

Friedman, 1999 — PubMed — Journal of Agricultural and Food Chemistry (1999) link

Safety

LiverTox: Phenylalanine — NIH NCBI Bookshelf — LiverTox (2020) link

Other references

D-phenylalanine on Wikidata — Wikidata link

D-phenylalanine on NIH DSLD — NIH Dietary Supplement Label Database link

Track D-phenylalanine with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store

Evidence-based·Last reviewed May 31, 2026·Evidence current as of May 31, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.